1-丙醇,3-(三苯基甲氧基)- | 17367-31-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 中文名称: 1-丙醇,3-(三苯基甲氧基)-
• 英文名称: 3-trityloxy-1-propanol
• 英文别名: 3-[(triphenylmethyl)oxy]propanol；3-(triphenylmethyloxy)propanol；3-Triphenylmethoxypropan-1-ol；5,5,5-triphenyl-4-oxapentanol；3-(triphenylmethoxy)propanol；3-(trityloxy)propan-1-ol；3-(Trityloxy)-1-propanol；3-trityloxypropan-1-ol
• CAS: 17367-31-6
• 化学式: C₂₂H₂₂O₂
• 分子量: 318.415
• InChiKey: YCTXPSAULMVEOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-丙醇,3-(三苯基甲氧基)- 在 N-甲基吗啉 、 potassium permanganate 、 草酰氯 、 二甲基亚砜 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 、 丙酮 、 乙腈 为溶剂， 反应 6.33h， 生成 N-(3-trityloxypropionyl)cysteamine
  参考文献：
  名称：

  New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine

  摘要：

  Cyclothialidine (1, Ro 09-1437) is a potent DNA gyrase inhibitor that was isolated from Streptomyces filipinensis NR0484 and is a member of a new family of natural products. It acts by competitively inhibiting the ATPase activity exerted by the B subunit of DNA gyrase but barely exhibits any growth inhibitory activity against intact bacterial cells, presumably due to insufficient permeation of the cytoplasmic membrane. To explore the antibacterial potential of 1, we developed a flexible synthetic route allowing for the systematic modification of its structure. From a first set of analogues, structure-activity relationships (SAR) were established for different substitution patterns, and the 14-hydroxylated, bicyclic core (X) of 1 seemed to be the structural prerequisite for DNA gyrase inhibitory activity. The variation of the lactone ring size, however, revealed that activity can be found among 11- to 16-membered lactones, and even seco-analogues were shown to maintain some enzyme inhibitory properties, thereby reducing the minimal structural requirements to a rather simple, hydroxylated benzyl sulfide (XI). On the basis of these "minimal structures" a modification program afforded a number of inhibitors that showed in vitro activity against Gram-positive bacteria. The best activities were displayed by 14-membered lactones, and representatives of this subclass exhibit excellent and broad in vitro antibacterial activity against Gram-positive pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, and overcome resistance against clinically used drugs. By improving the pharmacokinetic properties of the most active compounds (94, 97), in particular by lowering their lipophilic properties, we were able to identify congeners of cyclothialidine (1) that showed efficacy in vivo.

  DOI：

  10.1021/jm0310232
• 作为产物：
  描述：

  三苯基氯甲烷 、 1,3-丙二醇 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 1-丙醇,3-(三苯基甲氧基)-
  参考文献：
  名称：

  铜催化 β-酮酯烯醇三氟甲磺酸酯与格氏锌盐配合物立体选择性合成三取代和四取代 α,β-不饱和酯

  摘要：

  通过铜催化的β-酮酯的烯醇三氟甲磺酸酯与基于Grignard的锌配位复合物的偶联反应，立体选择性地合成了三取代和四取代的α,β-不饱和酯。文中还描述了一些对机理考虑的见解。

  DOI：

  10.1055/s-2001-17479

文献信息

• Highly Efficient Synthesis of Monodisperse Poly(ethylene glycols) and Derivatives through Macrocyclization of Oligo(ethylene glycols)
  作者：Hua Zhang、Xuefei Li、Qiuyan Shi、Yu Li、Guiquan Xia、Long Chen、Zhigang Yang、Zhong-Xing Jiang

  DOI：10.1002/anie.201410309

  日期：2015.3.16

  A macrocyclic sulfate (MCS)‐based approach to monodisperse poly(ethylene glycols) (M‐PEGs) and their monofunctionalized derivatives has been developed. Macrocyclization of oligo(ethylene glycols) (OEGs) provides MCS (up to a 62‐membered macrocycle) as versatile precursors for a range of monofunctionalized M‐PEGs. Through iterative nucleophilic ring‐opening reactions of MCS without performing group

  已开发出一种基于大环硫酸盐（MCS）的单分散聚乙二醇（M-PEG）及其单官能化衍生物的方法。寡聚乙二醇（OEG）的大环化提供了MCS（最多62个成员的大环），作为一系列单官能化M-PEG的通用前体。通过MCS的反复亲核开环反应而无需进行基团保护和激活，可以轻松制备一系列M-PEG，包括史无前例的64-mer（2850 Da）。合成简单性与这种新策略的多功能性可能为M-PEG的更广泛应用铺平道路。
• 双核苷酸前体药物
  申请人：博瑞生物医药（苏州）股份有限公司

  公开号：CN110467646A

  公开（公告）日：2019-11-19

  本发明提供了一种结构新颖的双核苷酸前体药物。还提供了所述双核苷酸前体药物的制备方法，以及其在制备治疗病毒感染，特别是乙型肝炎病毒(HBV)感染和与HBV有关的肝脏疾病药物的应用。这些双核苷前体化合物能够显著提高其在肝脏的靶向性，并提高其在肝部位的蓄积能力，进一步有效提高药效活性，并降低使用剂量，进而减少毒副作用；动物实验表明，体内在吸收之后，化合物迅速地从中央室分布到血管外的组织中，并在肝脏大量的集中，在其他组织中只观察到很少剂量。并且本发明提供的双核苷前体化合物还具有口服生物利用度高，在胃中稳定性好，体内半衰期长的优点。
• MELANIN PRODUCTION INHIBITOR
  申请人：Yokoyama Kouji

  公开号：US20110243865A1

  公开（公告）日：2011-10-06

  Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole), and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent, wherein at least one of A1, A2 and A3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group, wherein when one of R1 and R2 is an oxo group, the other is not present; and R3 is selected from a hydrogen atom, and a C 1-8 hydrocarbon group in which one or some of hydrogen atoms or carbon atoms may be substituted by a hetero atom or hetero atoms, wherein the number of R3's present in the compound corresponds to the number of X's and, when two or more R3's are present, the R3's are independently present and the adjacent two R3's may be bound to each other to form, together with X, a ring, and the terminal of R3 may be bound to a carbon atom to which A1, A2 and A3 are bound, thereby forming a ring.

  披露了一种黑色素生产抑制剂，它对黑色素的生产具有出色的抑制活性且高度安全。该黑色素生产抑制剂包括由通用公式（1）表示的化合物（不包括克霉唑）和/或其药理上可接受的盐。在公式中，A1、A2和A3独立地选自氢原子、可能带有取代基的芳基团和可能带有取代基的芳香杂环团，其中至少A1、A2和A3之一选自芳基团和芳香杂环团，A1、A2和A3中包含的碳原子总数为6至50，并且当至少两个A1、A2和A3表示芳基团或芳香杂环团时，相邻的两个芳基或芳香杂环团可以通过烷基链或烯基链相互连接形成环；m代表0至2的整数；X代表异原子、氢原子或碳原子；R1和R2独立地选自氢原子和氧代基，其中当R1和R2之一是氧代基时，另一个不出现；R3选自氢原子和C 1-8 碳氢化合物组，其中一些或所有的氢原子或碳原子可能被异原子或异原子取代，其中化合物中存在的R3的数量对应于X的数量，并且当存在两个或更多R3时，R3独立地存在，并且相邻的两个R3可以相互连接以与X一起形成环，并且R3的末端可以与A1、A2和A3连接的碳原子结合，从而形成环。
• Effect of Partially Fluorinated<i>N</i>-Alkyl-Substituted Piperidine-2-carboxamides on Pharmacologically Relevant Properties
  作者：Raffael Vorberg、Nils Trapp、Daniel Zimmerli、Björn Wagner、Holger Fischer、Nicole A. Kratochwil、Manfred Kansy、Erick M. Carreira、Klaus Müller

  DOI：10.1002/cmdc.201600325

  日期：2016.10.6

  energies, as indicated by variations in melting point temperatures. All fluorinated derivatives were found to be somewhat more readily oxidized in human liver microsomes, the rates of degradation correlating with increasing lipophilicity. Because the piperidine‐2‐carboxamide core is chiral, pairs with enantiomeric N‐alkyl groups are diastereomeric. While little response to such stereoisomerism was observed

  通过选择性地将1-3个氟原子引入n-丙基和n中，研究了N-烷基-哌啶-2-羧酰胺的药理相关特性的调节局部麻醉药罗哌卡因和左旋布比卡因的叔丁基侧链。附近氟取代基对碱的调节本质上是加和的，并且表现出随氟与碱中心之间的拓扑距离而变的指数衰减。中性哌啶衍生物的固有亲脂性显示出对连接至中性杂芳基系统的部分氟化烷基的特征响应。但是，附近的氟取代基引起的碱度降低会影响中性pH值的亲脂性，因此所有部分氟化的衍生物的亲脂性都比其未氟化的母体相似或更高。发现水溶性与亲脂性成反比，并且与晶体堆积能有很大关系，如熔点温度的变化所示。发现所有氟化衍生物在人肝微粒体中都更容易被氧化，降解速率与亲脂性增加相关。因为哌啶-2-羧酰胺核心是手性的，所以与对映异构体配对N-烷基是非对映异构的。虽然对于碱性或亲脂性几乎观察不到对这种立体异构的反应，但是对于熔点温度和氧化降解观察到更明显的变化。
• DNA gyrase inhibitors and pharmaceutical preparations therefor
  申请人：Hoffmann-LaRoche Inc.

  公开号：US05294609A1

  公开（公告）日：1994-03-15

  Bicyclic derivatives of the formula ##STR1## wherein X.sup.1, X.sup.2, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7a, R.sup.7b, and R.sup.8 are as defined in the specification. These compounds are antimicrobially active.

  公式为##STR1##的双环衍生物，其中X.sup.1、X.sup.2、R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7a、R.sup.7b和R.sup.8的定义如规范中所述。这些化合物具有抗微生物活性。